Gland Pharma Ltd receives EIR from USFDA for Pashamylaram Facility at Hyderabad

Gland Pharma Limited has announced that following the Pre-Approval Inspection (PAI) for Seven (7) products and Good Manufacturing Practice (GMP) Inspection by US FDA at the Company's Pashamylaram Facility at Hyderabad between 15th June, 2023 and 27th June, 2023, the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.

Shares of Gland Pharma Limited was last trading in BSE at Rs. 1659.65 as compared to the previous close of Rs. 1691.80. The total number of shares traded during the day was 10934 in over 1251 trades.

The stock hit an intraday high of Rs. 1744.10 and intraday low of 1645.00. The net turnover during the day was Rs. 18509033.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 USFDA EIR PashamylaramFacility Hyderabad